Welcome to our dedicated page for Avita Medical news (Ticker: RCEL), a resource for investors and traders seeking the latest updates and insights on Avita Medical stock.
Avita Medical Inc (RCEL) delivers breakthrough regenerative medicine solutions through its FDA-approved RECELL system, transforming wound care and skin restoration. This news hub provides investors and medical professionals with essential updates on clinical advancements, regulatory milestones, and strategic initiatives.
Access authoritative information about RCEL's innovative approach to burn treatment and skin repair, including FDA clearances, international regulatory progress, and partnerships shaping the future of point-of-care cell therapy. Our curated collection features press releases on product innovations, peer-reviewed research validations, and market expansion activities.
Key content categories include clinical trial outcomes, regulatory submissions, financial performance updates, and technological refinements to the RECELL platform. Users benefit from centralized access to verified information supporting informed analysis of this medical device innovator.
Bookmark this page for streamlined tracking of Avita Medical's progress in advancing regenerative wound care solutions. Check regularly for updates demonstrating how RCEL's patented technology continues to redefine standards in acute burn treatment and complex wound management.
AVITA Medical (NASDAQ: RCEL) reported Q1 2024 financial results. Key highlights include a 5.8% increase in commercial revenue to $11.1 million, and a gross profit margin of 86.4%. The company launched PermeaDerm, a biosynthetic wound matrix, in March.
Future milestones involve RECELL GO, undergoing a 180-day FDA review, with expectations to submit a PMA supplement for RECELL GO mini by year-end. Financial guidance projects Q2 revenue between $14.3-$15.3 million and full-year revenue at the lower end of $78.5-$84.5 million.
Expenses rose to $26.8 million due to increased sales, marketing, and R&D costs. Net loss widened to $18.7 million, or $0.73 per share, compared to $9.2 million, or $0.37 per share, in Q1 2023.
FAQ
What is the current stock price of Avita Medical (RCEL)?
What is the market cap of Avita Medical (RCEL)?
